Abstract
between vitamin D and PTH at 4-months post-LT (r: -0.26, P=0.019), while there was a trend toward an association between PTH at evaluation and MELD score at listing for LT (P=0.051). Conclusion: Vitamin D deficiency, in particular moderate-severe deficiency, was very prevalent in a cohort of patients undergoing evaluation for LT. Deficiency was improved with increased vitamin D (>400,00 IU) replacement therapy, indicating an opportunity for practice improvement. Vitamin D deficiency at LT was not associated with worse bone or functional outcomes post-LT. Patients receiving induction immunosuppressant therapy with basiliximab had a significantly greater degree of worsening in BMD post-LT. Table 1: Prevalence of Vitamin D Deficiency
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
